Illumina, Inc. — Q2 2016 Form 10-Q Summary
Business context and reporting period
Illumina develops DNA sequencing and array-based technologies for research, clinical, oncology, reproductive health, agriculture, and other applied markets. The filing covers the 13-week quarter and six months ended July 3, 2016, compared with the periods ended June 28, 2015.
Key financial metrics
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Total revenue | $600.1 million | $539.4 million | $1,171.9 million | $1,077.9 million |
| Gross profit / margin | $423.8 million / 70.6% | $376.4 million / 69.8% | $820.9 million / 70.0% | $751.4 million / 69.7% |
| Income from operations | $161.9 million | $151.9 million | $283.3 million | $328.1 million |
| Net income attributable to Illumina | $120.4 million | $102.2 million | $210.0 million | $238.9 million |
| Diluted EPS | $0.82 | $0.69 | $1.43 | $1.61 |
| Cash flow from operations | Not separately provided | Not separately provided | $256.8 million | $238.2 million |
Q2 revenue increased 11%, while first-half revenue increased 8.7%. First-half product revenue was $992.7 million and service and other revenue was $179.2 million. Consumables revenue increased 25% in Q2 and 21% year to date, while instrument revenue declined 19% in both comparisons. Service and other revenue increased 18% in Q2 and 15% year to date.
At July 3, 2016, cash and cash equivalents were $951.7 million and short-term investments were $473.6 million, for combined cash, cash equivalents, and short-term investments of approximately $1.4 billion. Cash and cash equivalents increased $182.9 million from January 3, 2016.
Total debt consisted primarily of $632.5 million of 0% convertible notes due 2019 and $517.5 million of 0.5% convertible notes due 2021. Net carrying value of long-term debt was $1.03 billion. The 2016 convertible notes were fully converted by March 11, 2016.
Material changes versus the prior comparable period
- Revenue growth was led by sequencing consumables and service revenue, partially offset by lower shipments of high-throughput instruments.
- Gross margin improved to 70.0% from 69.7% for the first half, primarily because of a greater mix of sequencing consumables; service margin declined.
- First-half operating income fell $44.7 million despite higher gross profit, as research and development expense rose 32% and selling, general and administrative expense rose 24%.
- First-half net income attributable to Illumina declined $28.9 million, reflecting higher operating expenses and the absence of a $12.6 million cost-method investment gain recognized in the prior-year period.
- Operating cash flow increased $18.6 million year over year. Investing cash use was nominal in the first half of 2016 versus $296.6 million in the prior-year period, largely because securities purchases and maturities were more closely balanced.
- Capital expenditures were $121.2 million, compared with $77.9 million in the prior-year period, primarily for facilities and manufacturing, research, and development equipment.
Guidance, outlook, risks, contingencies, and unusual items
Management expects sequencing demand and consumables revenue to continue growing, while array demand may shift toward lower-complexity products and some array studies may migrate to sequencing. Management identified stronger performance in the Americas and Asia Pacific and weaker performance in Europe, where it is taking steps to improve execution. No specific numerical revenue or earnings guidance is provided in the filing text.
Management expects current cash, cash equivalents, short-term investments, and operating cash flow to fund near-term operating and capital requirements for at least the next 12 months. Planned uses include commercialization, research and development, facilities, capital equipment, acquisitions and investments, potential debt repayment, and share repurchases. Approximately $156.1 million remained available under repurchase authorizations after $100.0 million of first-half repurchases.
- GRAIL was consolidated as a variable interest entity. Illumina held approximately 52% of GRAIL on a fully diluted basis and absorbed 90% of GRAIL’s losses through July 3, 2016; beginning July 4, 2016, its loss allocation was expected to be approximately 50%.
- Cash held by GRAIL and Helix totaled $123.6 million and was not available to settle Illumina’s obligations. Certain Helix investors may require cash redemption of their interests after January 1, 2021, subject to specified conditions.
- Illumina committed $100.0 million to a venture capital fund, callable over ten years; $6.3 million had been contributed or transferred during the first half.
- A July 1, 2016 settlement with Enzo Life Sciences required a $21.0 million payment. The company capitalized $11.5 million as a licensed intangible asset and recorded $9.5 million for past damages. A $11.5 million reversal of previously recorded legal contingency expense benefited Q2 operating results.
- The company identifies risks involving product development and commercialization, manufacturing, acquisitions, competition, taxation, litigation, economic conditions, foreign exchange, and the accuracy of accounting estimates. The filing states that no material changes occurred to the risk factors reported in the 2015 Form 10-K.
- Recent accounting standards concerning stock compensation, leases, and revenue recognition were not yet effective, and the company was evaluating their impact.
Important facts for investors to verify
- Reconcile the strong consumables growth and instrument decline with installed-base expansion, product mix, and future gross-margin expectations.
- Assess whether rising research and development, selling, general and administrative, and GRAIL/Helix costs will continue to pressure operating leverage.
- Review the liquidity and availability of cash held by foreign subsidiaries, GRAIL, and Helix, including potential tax or redemption constraints.
- Evaluate the maturity, conversion terms, and dilution implications of the 2019 and 2021 convertible notes.
- Monitor European execution, array-to-sequencing substitution, pricing pressure, service margins, and competitive product launches.
- Review the Enzo settlement, other legal proceedings, and any potential losses exceeding recorded accruals.
- Confirm the effect of GRAIL consolidation and changing loss allocations on future revenue, expenses, noncontrolling interests, and earnings per share.